Literature DB >> 9665156

Tetanus surveillance--United States, 1995-1997.

B Bardenheier1, D R Prevots, N Khetsuriani, M Wharton.   

Abstract

UNLABELLED: PROBLEM/CONDITIONS: Despite widespread availability of a safe and effective vaccine against tetanus, 124 cases of the disease were reported during 1995-1997. Only 13% of patients reported having received a primary series of tetanus toxoid (TT) before disease onset. Of patients with known illness outcome, the case-fatality ratio was 11%. REPORTING PERIOD COVERED: 1995-1997. DESCRIPTION OF SYSTEM: Physician-diagnosed cases of tetanus are reported by state and local health departments to CDC's National Notifiable Diseases Surveillance System. In addition, since 1965, supplemental clinical and epidemiologic information for cases has been provided to CDC's National Immunization Program.
RESULTS: From 1995 through 1997, a total of 124 cases of tetanus were reported from 33 states and the District of Columbia, accounting for an average annual incidence of 0.15 cases per 1,000,000 population. Sixty percent of patients were aged 20-59 years; 35% were aged > or =60 years; and 5% were aged <20 years, including one case of neonatal tetanus. For adults aged > or =60 years, the increased risk for tetanus was nearly sevenfold that for persons aged 5-19 years and twofold that for persons aged 20-59 years. The case-fatality ratio varied from 2.3% for persons aged 20-39 years to 16% for persons aged 40-59 years and to 18% for persons aged > or =60 years. Only 13% of patients reported having received a primary series of TT before disease onset. Previous vaccination status was directly related to severity of disease, with the case-fatality ratio ranging from 6% for patients who had received one to two doses to 15% for patients who were unvaccinated. No deaths occurred among the 16 patients who previously had received three or more doses. Tetanus occurred following an acute injury in 77% of patients, but only 41% sought medical care for their injury. All patients who sought care were eligible for TT as part of wound prophylaxis, but only 39% received it. Tetanus in injecting-drug users (IDUs) with no known acute injury comprised 11% of all cases, compared with 3.6% during 1991-1994. None of the IDU-associated tetanus cases occurred among persons who were known to have been vaccinated. Sixty-nine percent of IDU-associated tetanus cases were reported from California, and 77% of these cases occurred in heroin users.
INTERPRETATION: Tetanus remains a severe disease that primarily affects unvaccinated or inadequately vaccinated persons. Adults aged > or =60 years continue to be at highest risk for tetanus and for severe disease. However, the overall incidence of tetanus has decreased slightly since the late 1980s and early 1990s, from 0.20 to 0.15, a result primarily of a decreased incidence among persons aged > or =60 and <20 years. ACTIONS TAKEN: Tetanus is preventable through both routine vaccination and appropriate wound management. In addition to decennial booster doses of diphtheria and tetanus toxoids during adult life, the Advisory Committee on Immunization Practices (ACIP) recommends vaccination visits for adolescents at age 11-12 years and for adults at age 50 years to enable health-care providers to review vaccination histories and administer any needed vaccine. Every contact with the health-care system, particularly among older adults and IDUs, should be used to review and update vaccination status as needed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9665156

Source DB:  PubMed          Journal:  MMWR CDC Surveill Summ


  10 in total

1.  The seroepidemiology of tetanus in Catalonia, Spain.

Authors:  A Domínguez; P Plans; J Costa; J Espuñes; N Cardeñosa; L Salleras; A Plasència
Journal:  Med Microbiol Immunol       Date:  2007-01-23       Impact factor: 3.402

2.  Nationwide increase in hospitalizations for heroin-related soft tissue infections: Associations with structural market conditions.

Authors:  Daniel Ciccarone; George Jay Unick; Jenny K Cohen; Sarah G Mars; Daniel Rosenblum
Journal:  Drug Alcohol Depend       Date:  2016-04-14       Impact factor: 4.492

3.  [Coverage of anti-tetanus vaccinations in adults in Canada-year 2002. ].

Authors:  Norbert Coulibaly; Gaston De Serres
Journal:  Can J Public Health       Date:  2004 Nov-Dec

4.  The Textures of Heroin: User Perspectives on "Black Tar" and Powder Heroin in Two U.S. Cities.

Authors:  Sarah G Mars; Philippe Bourgois; George Karandinos; Fernando Montero; Daniel Ciccarone
Journal:  J Psychoactive Drugs       Date:  2016-07-20

5.  Impact of South American heroin on the US heroin market 1993-2004.

Authors:  Daniel Ciccarone; George J Unick; Allison Kraus
Journal:  Int J Drug Policy       Date:  2009-02-06

6.  Heroin in brown, black and white: structural factors and medical consequences in the US heroin market.

Authors:  Daniel Ciccarone
Journal:  Int J Drug Policy       Date:  2008-10-21

Review 7.  Postsurgical tetanus.

Authors:  Shayesta Dhalla
Journal:  Can J Surg       Date:  2004-10       Impact factor: 2.089

8.  A systematic review of tetanus in individuals with previous tetanus toxoid immunization.

Authors:  J P Hopkins; C Riddle; M Hollidge; S E Wilson
Journal:  Can Commun Dis Rep       Date:  2014-10-16

Review 9.  Soft Tissue, Bone, and Joint Infections in People Who Inject Drugs.

Authors:  Carlos S Saldana; Darshali A Vyas; Alysse G Wurcel
Journal:  Infect Dis Clin North Am       Date:  2020-09       Impact factor: 5.982

10.  Characteristic tetanus infection in disaster-affected areas: case study of the Yogyakarta earthquakes in Indonesia.

Authors:  Agung Budi Sutiono; Andri Qiantori; Hirohiko Suwa; Toshizumi Ohta
Journal:  BMC Res Notes       Date:  2009-03-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.